These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 10554037

  • 1. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Tsuchiya S, Nakagawa K, Hayashi J, Tsuchiya E.
    Cancer Res; 1999 Nov 01; 59(21):5572-7. PubMed ID: 10554037
    [Abstract] [Full Text] [Related]

  • 2. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M.
    Oncogene; 1998 May 14; 16(19):2469-77. PubMed ID: 9627113
    [Abstract] [Full Text] [Related]

  • 3. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM, Jassem E, Rosell R, Martínez-Roca M, Jassem J, Martínez-López E, Monzó M, Sánchez-Hernández JJ, Moreno I, Sánchez-Céspedes M.
    Oncogene; 1997 Dec 11; 15(24):2951-8. PubMed ID: 9416838
    [Abstract] [Full Text] [Related]

  • 4. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H.
    Cancer Res; 1998 Jan 15; 58(2):328-33. PubMed ID: 9443413
    [Abstract] [Full Text] [Related]

  • 5. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma.
    Tomizawa Y, Kohno T, Fujita T, Kiyama M, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, Nakajima T, Yokota J.
    Oncogene; 1999 Jan 28; 18(4):1007-14. PubMed ID: 10023676
    [Abstract] [Full Text] [Related]

  • 6. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].
    Irie K, Ishida H, Furukawa T, Koyanagi K, Miyamoto Y.
    Rinsho Byori; 1996 Jan 28; 44(1):32-41. PubMed ID: 8691638
    [Abstract] [Full Text] [Related]

  • 7. p53 null mutations detected by a p53 yeast functional assay predict a poor outcome in young esophageal carcinoma patients.
    Osugi H, Morimura K, Okuda E, Takemura M, Higashino M, Takada N, Kinoshita H.
    Int J Oncol; 2002 Sep 28; 21(3):637-41. PubMed ID: 12168111
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis.
    Mitsudomi T, Hamajima N, Ogawa M, Takahashi T.
    Clin Cancer Res; 2000 Oct 28; 6(10):4055-63. PubMed ID: 11051256
    [Abstract] [Full Text] [Related]

  • 9. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V, Ryberg D, Kure EH, Arab MO, Stangeland L, Myking AO, Haugen A.
    Clin Cancer Res; 2000 Mar 28; 6(3):1031-7. PubMed ID: 10741731
    [Abstract] [Full Text] [Related]

  • 10. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY, Chong IW, Chen FM, Wang JY, Cheng TL, Cheng YJ, Sheu CC, Hung SY, Yang MC, Lin SR.
    Cancer Lett; 2005 May 26; 222(2):195-204. PubMed ID: 15863268
    [Abstract] [Full Text] [Related]

  • 11. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.
    Clin Cancer Res; 2005 Jan 01; 11(1):232-41. PubMed ID: 15671551
    [Abstract] [Full Text] [Related]

  • 12. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
    Wagata T, Shibagaki I, Imamura M, Shimada Y, Toguchida J, Yandell DW, Ikenaga M, Tobe T, Ishizaki K.
    Cancer Res; 1993 Feb 15; 53(4):846-50. PubMed ID: 8094033
    [Abstract] [Full Text] [Related]

  • 13. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR.
    Clin Cancer Res; 2000 Aug 15; 6(8):3153-8. PubMed ID: 10955797
    [Abstract] [Full Text] [Related]

  • 14. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
    Tam AS, Foley JF, Devereux TR, Maronpot RR, Massey TE.
    Cancer Res; 1999 Aug 01; 59(15):3634-40. PubMed ID: 10446974
    [Abstract] [Full Text] [Related]

  • 15. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
    Kawasaki H, Ogura T, Yokose T, Nagai K, Nishiwaki Y, Esumi H.
    Hum Pathol; 2001 Oct 01; 32(10):1043-9. PubMed ID: 11679937
    [Abstract] [Full Text] [Related]

  • 16. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
    Gorgoulis VG, Zacharatos P, Mariatos G, Liloglou T, Kokotas S, Kastrinakis N, Kotsinas A, Athanasiou A, Foukas P, Zoumpourlis V, Kletsas D, Ikonomopoulos J, Asimacopoulos PJ, Kittas C, Field JK.
    Cancer Res; 2001 Jan 15; 61(2):538-49. PubMed ID: 11212247
    [Abstract] [Full Text] [Related]

  • 17. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA.
    Br J Cancer; 2000 Aug 15; 83(4):473-9. PubMed ID: 10945494
    [Abstract] [Full Text] [Related]

  • 18. Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma.
    Wang X, Christiani DC, Mark EJ, Nelson H, Wiencke JK, Gunn L, Wain JC, Kelsey KT.
    Cancer; 1999 Apr 15; 85(8):1734-9. PubMed ID: 10223567
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H.
    Cancer; 2002 Apr 15; 94(8):2239-47. PubMed ID: 12001123
    [Abstract] [Full Text] [Related]

  • 20. p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: an analysis of medically managed patients.
    Murakami I, Hiyama K, Ishioka S, Yamakido M, Kasagi F, Yokosaki Y.
    Clin Cancer Res; 2000 Feb 15; 6(2):526-30. PubMed ID: 10690534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.